CRISM Therapeutics Corporation (AMMCF) Discusses Progress in ChemoSeed Drug Delivery Platform and Upcoming Brain Tumor Clinical Trial Transcript
Summarize this article with:
SA Transcripts157.31K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call CRISM Therapeutics Corporation (AMMCF) Discusses Progress in ChemoSeed Drug Delivery Platform and Upcoming Brain Tumor Clinical Trial December 11, 2025 7:00 AM EST Company Participants Andrew Webb - CEO & Executive Director Presentation Operator Good afternoon, and welcome to the CRISM Therapeutics Corporation Investor Presentation. [Operator Instructions] Before we begin, I'd like to submit the following poll. I'd now like to hand you over to Andrew Webb, CEO. Good afternoon, sir. Andrew WebbCEO & Executive Director Good afternoon. Welcome to today's CRISM Therapeutics Corporation. Thank you very much for taking the time today. My name is Andrew Webb and the purpose of today's presentation is to update you on the significant progress we've made over recent months. Those of you who may recall the last update was in September. And clearly, today, it's in the context of seeking additional funding from our existing shareholders through a retail offer, which was published. This is a follow-on from a successful and oversubscribed placing, which the company did earlier in the week. So to start with an introduction, just a refresh, at CRISM Therapeutics, we are a drug delivery company working on how we can improve importantly the safety and efficacy of chemotherapy for cancer patients. If I may, just by virtue of an overview, just as a refresh, we call ourselves a platform for drug delivery company. So with-the technology that we have is, which is certainly ChemoSeed, will be available to and accessible to a number of solid tumor indications. What we're doing at the moment is, as I always give you a run-in to the clinical trial plans that we have. But just quickly on the technology itself, is the term ChemoSeed. ChemoSeed was the innovation of our-our Chief Scientist, Professor Chris McConville. He'd been working with -- in the oncology space for some Recommended For You